<p>Biogen（纳斯达克代码：BIIB - 获取免费报告）在周一向投资者发布的研究报告中，JPMorgan Chase &amp; Co.将其目标价格从 220.00 美元下调至 210.00 美元，Benzinga 报道。该券商目前对这家生物技术公司的股票给予 “中性” 评级。JPMorgan Chase &amp; Co.的目标价格意味着该股票当前价格有 21.30% 的潜在上涨空间。</p>
<ul>
<li>这三只股票被严重低估：抓住机会</li>
</ul>
<p>其他一些分析师最近也对该公司发布了报告。StockNews.com 在 9 月 2 日的报告中将 Biogen 的评级从 “买入” 上调至 “强力买入”。Piper Sandler 在 7 月 12 日的研究报告中将 Biogen 的目标价格从 335.00 美元下调至 313.00 美元，并对该股票给予 “超配” 评级。瑞银集团在 10 月 3 日的报告中将 Biogen 的目标价格从 234.00 美元下调至 202.00 美元，并对该公司给予 “中性” 评级。Robert W. Baird 在 7 月 29 日的报告中将 Biogen 的目标价格从 316.00 美元下调至 294.00 美元，并对该股票给予 “跑赢大盘” 评级。最后，Wedbush 在 9 月 23 日的研究报告中将 Biogen 的目标价格从 210.00 美元下调至 205.00 美元，并对该公司给予 “中性” 评级。十位分析师对该股票给予持有评级，十六位给予买入评级，一位给予强力买入评级。根据 MarketBeat.com 的数据，Biogen 目前的共识评级为 “适度买入”，共识目标价格为 261.58 美元。</p>
<p><strong>获取我们最新的 BIIB 研究报告</strong></p>
<h2>Biogen 价格表现</h2>
<ul>
<li>阿尔茨海默病药物股票：投资于 Eli Lilly、Biogen、Roche</li>
</ul>
<p>周一中午交易时，BIIB 的股价下跌 0.66 美元，达到 173.13 美元。该公司股票的交易量为 320,117 股，而其平均交易量为 1,130,322 股。Biogen 的 52 周低点为 170.71 美元，52 周高点为 268.30 美元。该公司的市值为 252.3 亿美元，市盈率为 15.50，PEG 比率为 1.73，贝塔值为-0.06。该公司的 50 日简单移动平均线为 192.71 美元，200 日简单移动平均线为 209.59 美元。该公司的速动比率为 1.48，流动比率为 1.26，债务股本比率为 0.28。</p>
<p>Biogen（纳斯达克代码：BIIB - 获取免费报告）最近于 10 月 30 日发布了其财报。这家生物技术公司报告本季度每股收益为 4.08 美元，超出市场共识预期的 3.77 美元，超出幅度为 0.31 美元。Biogen 的净利润率为 16.81%，股本回报率为 14.98%。该公司本季度的收入为 24.7 亿美元，而分析师预期为 24.3 亿美元。在去年同期，该公司每股收益为 4.36 美元。Biogen 本季度的收入同比下降了 2.5%。平均而言，卖方分析师预测 Biogen 在当前财年的每股收益为 16.36 美元。</p>
<h2>内部买卖情况</h2>
<ul>
<li>Moderna 股票因尖端个性化癌症疫苗而飙升</li>
</ul>
<p>在其他新闻中，内部人士 Priya Singhal 在 9 月 3 日的交易中出售了 431 股该股票。该股票以平均 204.22 美元的价格出售，总价值为 88,018.82 美元。出售完成后，该内部人士现在直接持有 5,316 股该公司的股票，价值约为 1,085,633.52 美元。这代表其持股比例下降了 0.00%。该交易已在证券交易委员会的法律文件中披露，可以通过此超链接访问。目前，企业内部人士持有该股票的比例为 0.16%。</p>
<h2>机构投资者对 Biogen 的看法</h2>
<p>一些机构投资者最近增加或减少了对 BIIB 的持股。Plato Investment Management Ltd 在第一季度将其在 Biogen 的持股增加了 82.8%。Plato Investment Management Ltd 现在持有 117 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度又购买了 53 股。意大利联合银行控股公司在第二季度购买了 Biogen 的新股份，价值 33,000 美元。EntryPoint Capital LLC 在第一季度获得了 Biogen 的新头寸，价值约为 36,000 美元。Versant Capital Management Inc 在第二季度将其在 Biogen 的持股增加了 123.2%。Versant Capital Management Inc 现在持有 154 股该生物技术公司的股票，价值 36,000 美元，此前在上个季度又购买了 85 股。最后，Blue Trust Inc.在第二季度将其在 Biogen 的持股增加了 249.0%。Blue Trust Inc.现在持有 178 股该生物技术公司的股票，价值 38,000 美元，此前在上个季度又购买了 127 股。87.93% 的股票由机构投资者和对冲基金持有。</p>
<h2>Biogen 公司简介</h2>
<p>（获取免费报告）</p>
<p>Biogen Inc.在美国、欧洲、德国、亚洲及国际上发现、开发、制造和提供治疗神经系统和神经退行性疾病的疗法。该公司提供用于多发性硬化症（MS）的 TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI 和 FAMPYRA；用于脊髓性肌萎缩症的 SPINRAZA；用于治疗阿尔茨海默病的 ADUHELM；用于治疗斑块型银屑病的 FUMADERM；参考 ENBREL 的 etanercept 生物类似药 BENEPALI；参考 HUMIRA 的 adalimumab 生物类似药 IMRALDI；参考 REMICADE 的 infliximab 生物类似药 FLIXABI；以及参考 LUCENTIS 的 ranibizumab 生物类似药 BYOOVIZ。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票比 Biogen 更好</li>
<li>投资石油股票的方式与原因</li>
<li>嘉年华或皇家加勒比——哪只邮轮股票有更大的上涨空间？</li>
<li>三只可以帮助抵御通货膨胀的杂货股票</li>
<li>Summit Therapeutics：他们的肺癌药物是否会改变游戏规则？</li>
<li>什么是盈利惊喜？</li>
<li>三只可能在 2025 年被收购的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg"/></p>
<p><em>这条即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 一种新的参与人工智能热潮的方式（在 11 月 19 日之前采取行动）（来自 Behind the Markets）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE5MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE5MQ"/></p>
<h2>你现在应该投资 1000 美元在 Biogen 吗？</h2>
<p>在考虑 Biogen 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Biogen 并不在名单上。</p>
<p>虽然 Biogen 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BIIB

<p>摩根大通已将 Biogen（NASDAQ:BIIB）的目标股价从 .00 下调至 .00，维持 “中性” 评级。此调整表明，从当前股价来看，潜在上涨空间为 21.30%。其他分析师也对其评级进行了调整，十位分析师持 “持有” 评级，十六位持 “买入” 评级，一位持 “强烈买入” 评级。Biogen 的股票表现显示，52 周低点为 .71，高点为 .30，市值为 .23 亿美元。该公司报告上个季度的每股收益为 .08，超出预期</p>

<p>Biogen (NASDAQ:BIIB - Get Free Report) had its price objective cut by JPMorgan Chase &amp; Co. from $220.00 to $210.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a &#34;neutral&#34; rating on the biotechnology company's stock. JPMorgan Chase &amp; Co.'s price target would indicate a potential upside of 21.30% from the stock's current price.</p>
<div class="lb-trans"><p>Biogen（纳斯达克代码：BIIB - 获取免费报告）在周一向投资者发布的研究报告中，JPMorgan Chase &amp; Co.将其目标价格从 220.00 美元下调至 210.00 美元，Benzinga 报道。该券商目前对这家生物技术公司的股票给予 “中性” 评级。JPMorgan Chase &amp; Co.的目标价格意味着该股票当前价格有 21.30% 的潜在上涨空间。</p>
</div><ul>
<li>These 3 Stocks Are Screaming Oversold: Seize the Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>这三只股票被严重低估：抓住机会</li>
</ul>
</div><p>A number of other analysts have also recently issued reports on the company. StockNews.com upgraded Biogen from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, September 2nd. Piper Sandler cut their target price on Biogen from $335.00 to $313.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, July 12th. UBS Group lowered their price objective on Biogen from $234.00 to $202.00 and set a &#34;neutral&#34; rating for the company in a report on Thursday, October 3rd. Robert W. Baird cut their target price on shares of Biogen from $316.00 to $294.00 and set an &#34;outperform&#34; rating on the stock in a report on Monday, July 29th. Finally, Wedbush reduced their price objective on Biogen from $210.00 to $205.00 and set a &#34;neutral&#34; rating for the company in a research report on Monday, September 23rd. Ten analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Biogen currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $261.58.</p>
<div class="lb-trans"><p>其他一些分析师最近也对该公司发布了报告。StockNews.com 在 9 月 2 日的报告中将 Biogen 的评级从 “买入” 上调至 “强力买入”。Piper Sandler 在 7 月 12 日的研究报告中将 Biogen 的目标价格从 335.00 美元下调至 313.00 美元，并对该股票给予 “超配” 评级。瑞银集团在 10 月 3 日的报告中将 Biogen 的目标价格从 234.00 美元下调至 202.00 美元，并对该公司给予 “中性” 评级。Robert W. Baird 在 7 月 29 日的报告中将 Biogen 的目标价格从 316.00 美元下调至 294.00 美元，并对该股票给予 “跑赢大盘” 评级。最后，Wedbush 在 9 月 23 日的研究报告中将 Biogen 的目标价格从 210.00 美元下调至 205.00 美元，并对该公司给予 “中性” 评级。十位分析师对该股票给予持有评级，十六位给予买入评级，一位给予强力买入评级。根据 MarketBeat.com 的数据，Biogen 目前的共识评级为 “适度买入”，共识目标价格为 261.58 美元。</p>
</div><p><strong>Get Our Latest Research Report on BIIB</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 BIIB 研究报告</strong></p>
</div><h2>Biogen Price Performance</h2>
<div class="lb-trans"><h2>Biogen 价格表现</h2>
</div><ul>
<li>Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche</li>
</ul>
<div class="lb-trans"><ul>
<li>阿尔茨海默病药物股票：投资于 Eli Lilly、Biogen、Roche</li>
</ul>
</div><p>Shares of BIIB traded down $0.66 during mid-day trading on Monday, reaching $173.13. 320,117 shares of the company's stock were exchanged, compared to its average volume of 1,130,322. Biogen has a 52-week low of $170.71 and a 52-week high of $268.30. The company has a market cap of $25.23 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 1.73 and a beta of -0.06. The company has a 50-day simple moving average of $192.71 and a two-hundred day simple moving average of $209.59. The company has a quick ratio of 1.48, a current ratio of 1.26 and a debt-to-equity ratio of 0.28.</p>
<div class="lb-trans"><p>周一中午交易时，BIIB 的股价下跌 0.66 美元，达到 173.13 美元。该公司股票的交易量为 320,117 股，而其平均交易量为 1,130,322 股。Biogen 的 52 周低点为 170.71 美元，52 周高点为 268.30 美元。该公司的市值为 252.3 亿美元，市盈率为 15.50，PEG 比率为 1.73，贝塔值为-0.06。该公司的 50 日简单移动平均线为 192.71 美元，200 日简单移动平均线为 209.59 美元。该公司的速动比率为 1.48，流动比率为 1.26，债务股本比率为 0.28。</p>
</div><p>Biogen (NASDAQ:BIIB - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, topping the consensus estimate of $3.77 by $0.31. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The firm had revenue of $2.47 billion during the quarter, compared to analysts' expectations of $2.43 billion. During the same period in the previous year, the company earned $4.36 EPS. Biogen's revenue for the quarter was down 2.5% on a year-over-year basis. On average, sell-side analysts predict that Biogen will post 16.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Biogen（纳斯达克代码：BIIB - 获取免费报告）最近于 10 月 30 日发布了其财报。这家生物技术公司报告本季度每股收益为 4.08 美元，超出市场共识预期的 3.77 美元，超出幅度为 0.31 美元。Biogen 的净利润率为 16.81%，股本回报率为 14.98%。该公司本季度的收入为 24.7 亿美元，而分析师预期为 24.3 亿美元。在去年同期，该公司每股收益为 4.36 美元。Biogen 本季度的收入同比下降了 2.5%。平均而言，卖方分析师预测 Biogen 在当前财年的每股收益为 16.36 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><ul>
<li>Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna 股票因尖端个性化癌症疫苗而飙升</li>
</ul>
</div><p>In other news, insider Priya Singhal sold 431 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $204.22, for a total value of $88,018.82. Following the completion of the sale, the insider now directly owns 5,316 shares of the company's stock, valued at approximately $1,085,633.52. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Priya Singhal 在 9 月 3 日的交易中出售了 431 股该股票。该股票以平均 204.22 美元的价格出售，总价值为 88,018.82 美元。出售完成后，该内部人士现在直接持有 5,316 股该公司的股票，价值约为 1,085,633.52 美元。这代表其持股比例下降了 0.00%。该交易已在证券交易委员会的法律文件中披露，可以通过此超链接访问。目前，企业内部人士持有该股票的比例为 0.16%。</p>
</div><h2>Institutional Investors Weigh In On Biogen</h2>
<div class="lb-trans"><h2>机构投资者对 Biogen 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in BIIB. Plato Investment Management Ltd raised its stake in shares of Biogen by 82.8% during the first quarter. Plato Investment Management Ltd now owns 117 shares of the biotechnology company's stock worth $25,000 after buying an additional 53 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Biogen during the second quarter worth $33,000. EntryPoint Capital LLC acquired a new position in shares of Biogen during the 1st quarter worth approximately $36,000. Versant Capital Management Inc grew its position in shares of Biogen by 123.2% in the second quarter. Versant Capital Management Inc now owns 154 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 85 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Biogen by 249.0% during the 2nd quarter. Blue Trust Inc. now owns 178 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 127 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对 BIIB 的持股。Plato Investment Management Ltd 在第一季度将其在 Biogen 的持股增加了 82.8%。Plato Investment Management Ltd 现在持有 117 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度又购买了 53 股。意大利联合银行控股公司在第二季度购买了 Biogen 的新股份，价值 33,000 美元。EntryPoint Capital LLC 在第一季度获得了 Biogen 的新头寸，价值约为 36,000 美元。Versant Capital Management Inc 在第二季度将其在 Biogen 的持股增加了 123.2%。Versant Capital Management Inc 现在持有 154 股该生物技术公司的股票，价值 36,000 美元，此前在上个季度又购买了 85 股。最后，Blue Trust Inc.在第二季度将其在 Biogen 的持股增加了 249.0%。Blue Trust Inc.现在持有 178 股该生物技术公司的股票，价值 38,000 美元，此前在上个季度又购买了 127 股。87.93% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Biogen Company Profile</h2>
<div class="lb-trans"><h2>Biogen 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.</p>
<div class="lb-trans"><p>Biogen Inc.在美国、欧洲、德国、亚洲及国际上发现、开发、制造和提供治疗神经系统和神经退行性疾病的疗法。该公司提供用于多发性硬化症（MS）的 TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI 和 FAMPYRA；用于脊髓性肌萎缩症的 SPINRAZA；用于治疗阿尔茨海默病的 ADUHELM；用于治疗斑块型银屑病的 FUMADERM；参考 ENBREL 的 etanercept 生物类似药 BENEPALI；参考 HUMIRA 的 adalimumab 生物类似药 IMRALDI；参考 REMICADE 的 infliximab 生物类似药 FLIXABI；以及参考 LUCENTIS 的 ranibizumab 生物类似药 BYOOVIZ。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Biogen</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?</li>
<li>What is an Earnings Surprise?</li>
<li>3 Stocks That Are Potential Takeover Targets in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Biogen 更好</li>
<li>投资石油股票的方式与原因</li>
<li>嘉年华或皇家加勒比——哪只邮轮股票有更大的上涨空间？</li>
<li>三只可以帮助抵御通货膨胀的杂货股票</li>
<li>Summit Therapeutics：他们的肺癌药物是否会改变游戏规则？</li>
<li>什么是盈利惊喜？</li>
<li>三只可能在 2025 年被收购的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BIIB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这条即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ A new way to play the AI boom (act before November 19) (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 一种新的参与人工智能热潮的方式（在 11 月 19 日之前采取行动）（来自 Behind the Markets）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE5MQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10191&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Biogen right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Biogen 吗？</h2>
</div><p>Before you consider Biogen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Biogen 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Biogen 并不在名单上。</p>
</div><p>While Biogen currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biogen 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

摩根大通的分析师将 Biogen（NASDAQ:BIIB）的目标价下调至 210 美元